BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Week in Review: Sinopharm Holding Guangzhou Co. Ltd to Raise $640 Million Through Bond Sale


3/11/2013 11:56:05 AM

by Richard Daverman, PhD

March 9, 2013 --Sinopharm Holdings, one of China’s big-three drug distributors, will issue $640 million of five-year corporate bonds that may be used to fund new acquisitions; Shanghai Fosun Pharma will buy $22.4 million of preferred stock in Saladax Biomedical, a US maker of diagnostic assays; EntreMed, a US biotech with strong China connections, raised $10.7 million from two China-specific institutional investment funds; Viva Biotech, a Shanghai pre-clinical CRO, formed a drug development partnership with Addex Therapeutics of Switzerland; China National Biotec Group announced a research collaboration with Riboxx Pharma, a German biopharma; WuXi PharmaTech signed a second agreement with OMT, a California company that produces transgenic animals; Sun Yat-sen University will collaborate with Johns Hopkins University to develop China’s next-generation clinical investigators; China may give the SFDA power to regulate the nation’s food supply in addition to drugs; and WuXi PharmaTech reported another year of steadily increasing growth for 2012, something it seems to do with metronomic regularity. More details….

Stock Symbols: (HK: 01099) (SHA: 600196; HK: 02196) (NSDQ: ENMD) (NYSE: WX)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES